NextCure, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- NextCure, Inc.
- Company name
- NextCure, Inc.
- Organisation type
- Industry
- Registered legal name
- NEXTCURE, INC.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001661059
- Legal Entity Identifier (LEI)
- 549300Y5PR6RJR1STI24
Related records
Trials (10)
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
- A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
- A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
- A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
- A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
- A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
- NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
- The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer